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The past decade has seen a growing catalogue of guidelines
for reporting ﬁndings of epidemiologic studies [1–4]. The
basic rationale of each of these guidelines is that these
efforts will ultimately improve the credibility of epidemi-
ological research and publications. Recently, the European
Journal of Epidemiology published the guide lines for
prognostic studies in genomics [5, 6]. In this issue the
journal includes the paper of the Gallo et al. entitled
‘STrengthening the Reporting of OBservational studies in
Epidemiology—Molecular Epidemiology (STROBE-ME).
In 2004, the STROBE initiative provided a checklist of 22
items to be reported in epidemiological studies. The pres-
ent STROBE-ME initiative builds on the STROBE State-
ment [2]. It is difﬁcult to suppress a ‘me-too’ feeling and
the question raised by Vandenbroucke comes to mind: for
whom do these guidelines toll [4]? Why do we need this
extension of the STROBE statement given the abundance
guidance?
Building upon STROBE, STROBE-ME focuses specif-
ically on biomarkers. A biomarker is a characteristic that
can be objectively measured and evaluated as an indicator
of pathogenic processes. There is no doubt that biomarkers
have been highly valuable in epidemiological research
capturing exposures, providing quantitative measurements,
improving diagnosis and last but not least identifying high
risk groups for prevention and interventions. Despite these
successes, molecular epidemiologic research of the past
decades has taught us that discovery of plasma biomarkers
for major diseases is more challenging than anticipated. It
may be argued that the ‘‘one biomarker-one phenotype’’
assumption may have been a too simplistic approach. The
large number of biological processes that may underlie the
pathogenesis of complex diseases such as cardiovascular
disease, cancer and dementia predict that multiple bio-
markers are needed to capture the diversity. New devel-
opments in –omics technology including lipidomics,
metabolomics and proteomics will make proteome wide
approaches feasible in the near future and will boost
research molecular epidemiologic research. However,
ﬁndings using the new –omics technology have been dif-
ﬁcult to reproduce, resulting even in law-suits investigating
possibilities of fraud in reporting [7]. This puts the
reporting of key information in biomarker research back on
the agenda.
It is without a doubt that STROBE-ME targets a timely
issue in epidemiology, that is biomarker research in epi-
demiology [8–13]. The items added to STROBE concern
collection, handling and storage of biological samples,
laboratory methods, validity and reliability of biomarkers,
special study designs and ethical considerations. The items
addressed differ from those reported by recent guidelines
focusing on genetics [3, 5]. As the quest for biomarkers for
common diseases will enter a new era, STROBE-ME is a
valuable addition to the collection of guidelines.
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